<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
  
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">DIJ</journal-id>
      <journal-id journal-id-type="hwp">spdij</journal-id>
      <journal-title>Therapeutic Innovation &amp; Regulatory Science</journal-title>
      <issn pub-type="ppub">2168-4790</issn>
      <issn pub-type="epub">2164-9200</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.1177/2168479012460757</article-id>
      <article-id pub-id-type="publisher-id">10.1177_2168479012460757</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Drug Information</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Expanding Consumer Medication Access</article-title>
        <subtitle>The Time Is Now</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Huston</surname>
            <given-names>Sally A.</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="aff1-0092861512460757">1</xref>
          <xref ref-type="corresp" rid="corresp1-0092861512460757"/>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Kucukarslan</surname>
            <given-names>Suzan</given-names>
          </name>
          <degrees>MBA, PhD, RPh</degrees>
          <xref ref-type="aff" rid="aff2-0092861512460757">2</xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Harshali K.</given-names>
          </name>
          <degrees>MS</degrees>
          <xref ref-type="aff" rid="aff3-0092861512460757">3</xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Sogol</surname>
            <given-names>Elliott M.</given-names>
          </name>
          <degrees>RPh, PhD, FAPhA</degrees>
          <xref ref-type="aff" rid="aff4-0092861512460757">4</xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Ried</surname>
            <given-names>L. Douglas</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="aff5-0092861512460757">5</xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Sansgiry</surname>
            <given-names>Sujit S.</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="aff3-0092861512460757">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-0092861512460757"><label>1</label>Department of Clinical and Administrative
        Pharmacy, College of Pharmacy, University of Georgia, Athens, GA, USA</aff>
      <aff id="aff2-0092861512460757"><label>2</label>University of Michigan College of Pharmacy,
        Ann Arbor, MI, USA</aff>
      <aff id="aff3-0092861512460757"><label>3</label>Division of Pharmacy Administration and Public
        Health, Department of Clinical Sciences and Administration, College of Pharmacy, University
        of Houston, Houston, TX, USA</aff>
      <aff id="aff4-0092861512460757"><label>4</label>Target Professional Services, Minneapolis, MN,
        USA</aff>
      <aff id="aff5-0092861512460757"><label>5</label>University of South Florida, College of
        Pharmacy, Tampa, FL, USA</aff>
      <author-notes>
        <corresp id="corresp1-0092861512460757">Sally A. Huston, PhD, Department of Clinical and
          Administrative Pharmacy, College of Pharmacy, University of Georgia, 250 W. Green St.,
          Athens, GA, 30606, USA. Email: <email xlink:type="simple">shuston@rx.uga.edu</email>
        </corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>3</month>
        <year>2013</year>
      </pub-date>
      <volume>47</volume>
      <issue>2</issue>
      <fpage>183</fpage>
      <lpage>189</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>6</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>8</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© The Author(s) 2013</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder content-type="other">Drug Information Association</copyright-holder>
      </permissions>
      <abstract>
        <p>The US FDA is proposing an expanded over-the-counter (OTC) medication policy to improve
          patient access to medications under the supervision of a pharmacist. Higher levels of
          medication access via multiple medication categories are common in other industrialized
          nations. Pharmacists are well trained and widely available. Expanding medication access
          can help alleviate the physician shortage by directing patients with appropriate health
          conditions that can be managed with medication to community pharmacists. Examples include
          migraine headaches and seasonal allergies, which have a significant impact on patients’
          quality of life and work productivity. Clinically relevant medications and dosages should
          be selected. Medication use guidelines should not be so restrictive as to defeat the
          policy intent. The proposed FDA policy is a long-overdue change that will help optimize
          available health personnel resources for patient care.</p>
      </abstract>
      <kwd-group>
        <kwd>BTC</kwd>
        <kwd>expanded OTC</kwd>
        <kwd>medication access</kwd>
        <kwd>physician shortage</kwd>
        <kwd>pharmacist only</kwd>
        <kwd>pharmacist role</kwd>
        <kwd>pharmacy access</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="section1-0092861512460757">
      <title>Introduction</title>
      <p>For over 60 years there have been 2 medication classes in the United States: (1)
        over-the-counter (OTC) products, widely available and considered safe for use by consumers
        without medical supervision, and (2) prescription medications, available for use only under
        a prescriber’s supervision.<sup>
          <xref ref-type="bibr" rid="bibr1-0092861512460757">1</xref>
        </sup> Since then the number of medications has increased exponentially. The level of
        sophistication needed to safely and effectively use these medications varies widely. Some
        require only minimal knowledge easily obtained from package labeling, some require midlevel
        knowledge for safe and effective use, and others require a physician’s expertise.
        Correspondingly, health care services are evolving to improve the safe and effective use of
        medications (ie, evidence-based guidelines, increase in ancillary health care
        professionals). As a result, the level of health care expertise and oversight needed for
        safe and effective medication use should no longer be neatly divided into 2 levels.
        Recently, the FDA proposed to allow certain medications, otherwise obtainable only by
        prescription, to be made available to consumers as OTC under “conditions of safe use.”<sup>
          <xref ref-type="bibr" rid="bibr2-0092861512460757">2</xref>
        </sup> The FDA is proposing this new paradigm to increase consumer access to these
        medications while ensuring appropriate oversight for safe and effective use. The term
          <italic>expanded OTC</italic> is the designation used in this article to represent
        medications available as an OTC available “only with certain conditions for safe use.”</p>
      <p>The need for better access to health care services and medications is escalating. The 2010
        Patient Protection and Affordable Care Act is expected to result in an increase in the
        number of primary care visits of between 15.07 and 24.26 million annually by 2019.<sup>
          <xref ref-type="bibr" rid="bibr3-0092861512460757">3</xref>
        </sup> The number of necessary primary care providers is projected to be insufficient,
        resulting in a gap between demand for health care and availability of health care services.<sup>
          <xref ref-type="bibr" rid="bibr4-0092861512460757">4</xref>
        </sup> Improving patient access to expanded OTC medications under the clinical guidance of
        pharmacists has the potential to help fill that gap.</p>
      <p>Interest in increasing access to medications that experts concur would be safe and
        effective with a pharmacist’s clinical guidance has been growing.<sup>
          <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
          <xref ref-type="bibr" rid="bibr6-0092861512460757"/>
          <xref ref-type="bibr" rid="bibr7-0092861512460757"/>–<xref ref-type="bibr" rid="bibr8-0092861512460757">8</xref>
        </sup> In 1995, the General Accounting Office (GAO) studied the idea of a behind-the-counter
        (BTC) medication class, much like the current expanded OTC proposal, but found evidence was
        insufficient to support BTC class creation.<sup>
          <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
        </sup> They did not find evidence that having additional medication classes improved public
        health nor that pharmacists were ready and willing to counsel patients.<sup>
          <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
        </sup> Since then more evidence has been garnered regarding both pharmacist-provided
        clinical services<sup>
          <xref ref-type="bibr" rid="bibr9-0092861512460757">9</xref>
        </sup> and pharmacist-controlled medications in other countries.<sup>
          <xref ref-type="bibr" rid="bibr6-0092861512460757">6</xref>
        </sup>
      </p>
      <p>A recent article discussed various organizations positions for or against expanded OTC access.<sup>
          <xref ref-type="bibr" rid="bibr7-0092861512460757">7</xref>
        </sup> Pharmacy organizations tend to support an expanded OTC class, believing the category
        will enhance patient access to medications. Most consumer organizations also support an
        expanded OTC class, although the Consumer Healthcare Products Association has stated a
        concern that patient empowerment would be reduced.<sup>
          <xref ref-type="bibr" rid="bibr10-0092861512460757">10</xref>
        </sup> The opposite may be true however as a greater number of medications should be
        available to consumers without a prescription. Physician groups tend to oppose an expanded
        OTC class, expressing concerns about patient safety and health care fragmentation.<sup>
          <xref ref-type="bibr" rid="bibr7-0092861512460757">7</xref>
        </sup> Currently there are national efforts to improve health care provider communication
        and collaboration via the implementation of electronic health systems.<sup>
          <xref ref-type="bibr" rid="bibr11-0092861512460757">11</xref>
        </sup> Pharmacy should be included in these and future programs to foster communication and
        collaboration in regard to medications, including expanded OTC medicines. Recently, the
        American Medical Association House of Delegates stated their opposition to legislation
        “allowing pharmacists to independently prescribe or dispense prescription medication,”
        stating that pharmacist training is “not equivalent to that of physicians.”<sup>
          <xref ref-type="bibr" rid="bibr12-0092861512460757">12</xref>
        </sup> An expanded OTC access category of medications would not allow independent pharmacist
        prescribing and would not include medications safe for use only under the guidance of a
        physician.</p>
      <p>The FDA, with assistance from an expert review panel or an advisory committee, would
        designate expanded OTC medications deemed safe and effective for consumers to use without a
        prescription, but with the supervision of a health professional (eg, pharmacist).<sup>
          <xref ref-type="bibr" rid="bibr7-0092861512460757">7</xref>
        </sup> These health professionals would provide patients with clinical services such as
        screening and assessment, verifying disease diagnosis with a prescriber, providing written
        and verbal information, reviewing current medications, counseling, and/or monitoring to
        ensure safe and effective medication use.<sup>
          <xref ref-type="bibr" rid="bibr7-0092861512460757">7</xref>
        </sup> Lessons can be learned from similar medication policy changes in the US (eg,
        expansion of pharmacist vaccinations,<sup>
          <xref ref-type="bibr" rid="bibr13-0092861512460757">13</xref>
        </sup> Florida Pharmacist Self-Care Consultant Law) and in other industrialized countries
        (see below).<sup>
          <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
        </sup>
      </p>
    </sec>
    <sec id="section2-0092861512460757">
      <title>Pharmacists and Expanded OTC Medications</title>
      <p>The report to the US Surgeon General, <italic>Improving Patient and Health System Outcomes
          through Advanced Pharmacy Practice</italic>, provides an evidence-based discussion for
        expanding pharmacist services.<sup>
          <xref ref-type="bibr" rid="bibr9-0092861512460757">9</xref>
        </sup> Since 2000, graduating pharmacists have had a minimum of 6 years of education. In
        addition to extensive pharmaceutical knowledge, pharmacists can perform patient assessment;
        order, interpret, and monitor laboratory tests; provide clinical assessments and therapeutic
        plans; support patient coordination activities for preventive care services; and develop
        ongoing patient care services. Medication management services provided by pharmacists in the
        community have been shown to improve patient outcomes and reduce health care costs.<sup>
          <xref ref-type="bibr" rid="bibr9-0092861512460757">9</xref>
        </sup>
      </p>
      <p>Pharmacist-administered vaccinations provide a good example of how expanding pharmacist
        services can have a positive impact on public welfare. Patients benefit from easy access to
        safe and effective immunization services. Pharmacists screen their patients for any
        contraindications and inform them about vaccine-associated benefits and risks. A 2004 study
        showed states with pharmacist-administered vaccines (n = 30) had significantly higher
        influenza vaccination rates than states not allowing pharmacists to administer vaccines (n = 20).<sup>
          <xref ref-type="bibr" rid="bibr13-0092861512460757">13</xref>
        </sup> Now all 50 states allow it, and many insurance companies reimburse pharmacists for
        immunization services. Today’s community pharmacists provide vaccinations for influenza,
        pneumococcal disease, meningococcal disease, shingles, and others.</p>
    </sec>
    <sec id="section3-0092861512460757">
      <title>Medication Classification Systems</title>
      <p>Multiple levels of medication access, guidance, and supervision are not new among
        industrialized nations (<xref ref-type="table" rid="table1-0092861512460757">Table 1</xref>).<sup>
          <xref ref-type="bibr" rid="bibr6-0092861512460757">6</xref>,<xref ref-type="bibr" rid="bibr14-0092861512460757">14</xref>
          <xref ref-type="bibr" rid="bibr15-0092861512460757"/>
          <xref ref-type="bibr" rid="bibr16-0092861512460757"/>–<xref ref-type="bibr" rid="bibr17-0092861512460757">17</xref>
        </sup> For example, Canada, Australia, and New Zealand have 3 nonprescription drug
        categories: pharmacist only (requiring pharmacist intervention), pharmacy only (sale on
        pharmacy premises), and an unscheduled class for nonpharmacy outlets.<sup>
          <xref ref-type="bibr" rid="bibr7-0092861512460757">7</xref>,<xref ref-type="bibr" rid="bibr18-0092861512460757">18</xref>
        </sup> The UK also has a class requiring a pharmacist consultation.<sup>
          <xref ref-type="bibr" rid="bibr6-0092861512460757">6</xref>
        </sup> The 2009 GAO report on the third-class of medications (internationally also referred
        to as BTC) estimated 49% to 55% of medications in the US required a prescription, compared
        with 27% to 32% in Australia and 27% to 39% in the UK.<sup>
          <xref ref-type="bibr" rid="bibr6-0092861512460757">6</xref>,<xref ref-type="bibr" rid="bibr19-0092861512460757">19</xref>
        </sup> Under the current US drug classification system, 45% to 50% of medications are
        available for general sale, compared to only 11% to 27% in Australia and 5% to 34% in the UK.<sup>
          <xref ref-type="bibr" rid="bibr6-0092861512460757">6</xref>,<xref ref-type="bibr" rid="bibr19-0092861512460757">19</xref>
        </sup> Consequently, US consumers potentially face more risk for adverse drug events than
        consumers in countries with more than 2 medication classes and more health professional
        oversight for a greater number of medications (<xref ref-type="table" rid="table2-0092861512460757">Table 2</xref>).<sup>
          <xref ref-type="bibr" rid="bibr6-0092861512460757">6</xref>,<xref ref-type="bibr" rid="bibr14-0092861512460757">14</xref>
          <xref ref-type="bibr" rid="bibr15-0092861512460757"/>
          <xref ref-type="bibr" rid="bibr16-0092861512460757"/>–<xref ref-type="bibr" rid="bibr17-0092861512460757">17</xref>
        </sup> For example, the recent widespread recreational abuse of dextromethorphan, an OTC
        cough suppressant, is a growing concern in the US.<sup>
          <xref ref-type="bibr" rid="bibr20-0092861512460757">20</xref>
        </sup> In contrast, dextromethorphan abuse is less significant in countries where it is
        available as a pharmacy-/pharmacist-only medication,<sup>
          <xref ref-type="bibr" rid="bibr6-0092861512460757">6</xref>
        </sup> such as Australia, the Netherlands, and the UK.<sup>
          <xref ref-type="bibr" rid="bibr21-0092861512460757">21</xref>
        </sup>
      </p>
      <table-wrap id="table1-0092861512460757" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Drug Classification Systems Across Different Industrialized Countries.</p>
        </caption>
        <graphic alt-version="no" alternate-form-of="table1-0092861512460757" position="float" xlink:href="10.1177_0092861512460757-table1.tif" xlink:type="simple"/>
        <table>
          <thead>
            <tr>
              <th colspan="1" rowspan="1">Drug Classification</th>
              <th colspan="7" rowspan="1">Terminology and Availability in Different Countries</th>
            </tr>
            <tr>
              <th colspan="1" rowspan="1"> </th>
              <th colspan="1" rowspan="1">Australia</th>
              <th colspan="1" rowspan="1">Canada</th>
              <th colspan="1" rowspan="1">France</th>
              <th colspan="1" rowspan="1">Italy</th>
              <th colspan="1" rowspan="1">New Zealand</th>
              <th colspan="1" rowspan="1">United Kingdom</th>
              <th colspan="1" rowspan="1">United States</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td colspan="1" rowspan="1">Prescription only<sup>a</sup>
              </td>
              <td colspan="1" rowspan="1">Schedule 4 (S4)</td>
              <td colspan="1" rowspan="1">Schedule I</td>
              <td colspan="1" rowspan="1">List A and B</td>
              <td colspan="1" rowspan="1">Prescription only</td>
              <td colspan="1" rowspan="1">Prescription medicine</td>
              <td colspan="1" rowspan="1">Prescription-only medication (POM) </td>
              <td colspan="1" rowspan="1">Prescription only</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Pharmacist only<sup>b</sup>
              </td>
              <td colspan="1" rowspan="1">Schedule 3 (S3)</td>
              <td colspan="1" rowspan="1">Schedule II</td>
              <td colspan="1" rowspan="1">—</td>
              <td colspan="1" rowspan="1">—</td>
              <td colspan="1" rowspan="1">Restricted medicine</td>
              <td colspan="1" rowspan="1">Pharmacist-only (P) </td>
              <td colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Pharmacy only<sup>c</sup>
              </td>
              <td colspan="1" rowspan="1">Schedule 2 (S2)</td>
              <td colspan="1" rowspan="1">Schedule III</td>
              <td colspan="1" rowspan="1">Pharmacy-only/non prescription</td>
              <td colspan="1" rowspan="1">NP - presence of pharmacist in the premise</td>
              <td colspan="1" rowspan="1">Pharmacy medicine</td>
              <td colspan="1" rowspan="1"> —</td>
              <td colspan="1" rowspan="1">—<sup>e</sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Over-the-counter (OTC) products<sup>d</sup>
              </td>
              <td colspan="1" rowspan="1">General sale (GSL)/unscheduled products</td>
              <td colspan="1" rowspan="1">All retail outlets</td>
              <td colspan="1" rowspan="1">—</td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">All outlets</td>
              <td colspan="1" rowspan="1">General sale (GSL)</td>
              <td colspan="1" rowspan="1">OTC</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table-fn1-0092861512460757">
            <p>
              <sup>a</sup>To be prescribed by personnel approved by the state/territory legislation
              (usually physicians or veterinarians).</p>
          </fn>
          <fn id="table-fn2-0092861512460757">
            <p>
              <sup>b</sup>The safe use of medication requires professional advice and should be
              available from a pharmacist without prescription.</p>
          </fn>
          <fn id="table-fn3-0092861512460757">
            <p>
              <sup>c</sup>The medication should be available without a prescription only at a
              pharmacy, and the safe use of it may require pharmacist supervision.</p>
          </fn>
          <fn id="table-fn4-0092861512460757">
            <p>
              <sup>d</sup>Medications should be available from general retail outlets such as
              supermarket/pharmacies.</p>
          </fn>
          <fn id="table-fn5-0092861512460757">
            <p>
              <sup>e</sup>Certain controlled substance (pseudoephedrine, emergency contraceptives,
              etc) are available behind the counter after age and identity verification.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="table2-0092861512460757" position="float">
        <label>Table 2.</label>
        <caption>
          <p>Potential Expanded OTC Access Candidates.</p>
        </caption>
        <graphic alt-version="no" alternate-form-of="table2-0092861512460757" position="float" xlink:href="10.1177_0092861512460757-table2.tif" xlink:type="simple"/>
        <table>
          <thead>
            <tr>
              <th colspan="1" rowspan="1">Medical Condition</th>
              <th colspan="1" rowspan="1">Drug Class</th>
              <th colspan="1" rowspan="1">Medications</th>
              <th colspan="1" rowspan="1">Access Status Selected Countries</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td colspan="1" rowspan="1">Allergy</td>
              <td colspan="1" rowspan="1">Antihistamine</td>
              <td colspan="1" rowspan="1">Cyproheptadine<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">BTC in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup> and UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Fexofenadine<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Hydroxyzine<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Nasal corticosteroid<sup>
                  <xref ref-type="bibr" rid="bibr14-0092861512460757">14</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">Beclomethasone<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; OTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Budesonid<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Flunisolide<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Fluticasone<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Mometasone<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>,<xref ref-type="bibr" rid="bibr15-0092861512460757">15</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Angina</td>
              <td colspan="1" rowspan="1">Vasodilator</td>
              <td colspan="1" rowspan="1">Nitroglycerin<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>,<xref ref-type="bibr" rid="bibr15-0092861512460757">15</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Asthma, bronchospasm</td>
              <td colspan="1" rowspan="1">Beta-agonist</td>
              <td colspan="1" rowspan="1">Salbutamol<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">BTC in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Bronchodilator</td>
              <td colspan="1" rowspan="1">Theophylline<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">BTC in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Burns, minor</td>
              <td colspan="1" rowspan="1">Antibacterial</td>
              <td colspan="1" rowspan="1">Silver sulfadiazine 1%<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>,<xref ref-type="bibr" rid="bibr15-0092861512460757">15</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">OTC/P Italy</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Cholesterol lowering<sup>
                  <xref ref-type="bibr" rid="bibr14-0092861512460757">14</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Simvastatin<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>,<xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Cold sores</td>
              <td colspan="1" rowspan="1">Antiviral</td>
              <td colspan="1" rowspan="1">Penciclovir<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; OTC/P in Italy<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; OTC in Netherlands<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Eye infection</td>
              <td colspan="1" rowspan="1">Antibacterial, topical ophthalmic</td>
              <td colspan="1" rowspan="1">Chloramphenicol<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup> (physician referral if not resolved quickly)</td>
              <td colspan="1" rowspan="1">BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Fungus, topical or vaginal</td>
              <td colspan="1" rowspan="1">Antifungal</td>
              <td colspan="1" rowspan="1">Econazole<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">OTC in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; OTC/P in Italy<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; D in Netherlands<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Nystatin<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Migraine <sup>
                  <xref ref-type="bibr" rid="bibr14-0092861512460757">14</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">Triptan<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">Sumatriptan<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>,<xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; OTC in Mexico<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Motion sickness</td>
              <td colspan="1" rowspan="1">Antimuscarinic</td>
              <td colspan="1" rowspan="1">Hyoscine (scopolamine)<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; OTC/P in Italy<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; D in Netherlands<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Nausea</td>
              <td colspan="1" rowspan="1">Antiemetic</td>
              <td colspan="1" rowspan="1">Metoclopramide<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">BTC in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Prochlorperazine<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">OTC in Korea<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>; OTC in New Zealand<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Promethazine<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>,<xref ref-type="bibr" rid="bibr15-0092861512460757">15</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; D in Netherlands<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Pain, short-term relief</td>
              <td colspan="1" rowspan="1">Anesthetic, topical</td>
              <td colspan="1" rowspan="1">Prilocaine<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>,<xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; D in Netherlands<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; OTC in Canada, Korea, Mexico, New Zealand, Singapore<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Oxybuprocaine<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">OTC in Canada<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>; OTC in Singapore<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">NSAID</td>
              <td colspan="1" rowspan="1">Diclofenac<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>,<xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; OTC/P in Italy<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; D in Netherlands<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Flurbiprofen lozenges (sore throat)<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; OTC/P Italy<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Ibuprofen<sup>
                  <xref ref-type="bibr" rid="bibr17-0092861512460757">17</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">Suggested change from OTC to BTC, Canada<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>; OTC/P in Italy<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Opioid derivative combination</td>
              <td colspan="1" rowspan="1">Acetaminophen and dihydrocodeine<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">OTC in Australia<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Pain and/or antitussive</td>
              <td colspan="1" rowspan="1">Opioid derivative</td>
              <td colspan="1" rowspan="1">Dihydrocodeine<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">OTC in Australia<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>; OTC in Japan<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Pulmonary<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">Mucolytic</td>
              <td colspan="1" rowspan="1">Acetylcysteine</td>
              <td colspan="1" rowspan="1">OTC in Australia and Netherlands<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; P in Italy<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"> </td>
              <td colspan="1" rowspan="1">Nicotine replacement</td>
              <td colspan="1" rowspan="1">Nicotine (oral or nasal inhaler)<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>,<xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup> and Italy<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>,<xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>; D in Netherlands<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; OTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup> and New Zealand<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512460757">16</xref>
                </sup>
              </td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Worms</td>
              <td colspan="1" rowspan="1">Anthelmintic</td>
              <td colspan="1" rowspan="1">Mebendazole<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>,<xref ref-type="bibr" rid="bibr15-0092861512460757">15</xref>
                </sup>
              </td>
              <td colspan="1" rowspan="1">P in Australia<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; D in Netherlands<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>; BTC in UK<sup>
                  <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
                </sup>
              </td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table-fn6-0092861512460757">
            <p>BTC, behind the counter; D, drugstore; NSAID, nonsteroidal antiinflammatory drug;
              OTC, over the counter; OTC/P = over the counter but pharmacist required; P,
              pharmacy.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>A successful example of improved medication access and role optimization for pharmacists in
        a substitutive role at a nationwide level is the Scottish Minor Ailments Scheme (MAS).<sup>
          <xref ref-type="bibr" rid="bibr22-0092861512460757">22</xref>
        </sup> Implemented in 2006, the MAS allows pharmacists to prescribe medications for minor
        ailments (eg, malathion for head lice and clotrimazole for vaginal thrush).<sup>
          <xref ref-type="bibr" rid="bibr23-0092861512460757">23</xref>
        </sup> Economically disadvantaged patients have benefited the most from increased access to
        medications and pharmacists. Since its inception, patient participation in the MAS has been increasing.<sup>
          <xref ref-type="bibr" rid="bibr22-0092861512460757">22</xref>
        </sup> Interestingly, the Scottish MAS program reduced the number of physician visits for
        minor ailments but not the total number of physician visits.<sup>
          <xref ref-type="bibr" rid="bibr24-0092861512460757">24</xref>
        </sup> More physician time was spent for more complex cases, as anticipated. Hence, improved
        access to medication with a new class in the US should also improve patient access to
        physician services for more serious conditions.</p>
      <p>Each medication under consideration for expanded OTC status will need a thoughtful
        assessment as to what conditions will reasonably assure usefulness, access, and safety.
        Conditions for safe use might allow pharmacist recommendations for limited or specific
        indications, identify contraindications, require a lab test, specify only certain doses,
        package sizes or dosage forms, and/or indicate conditions for which physician or other (eg,
        sexual health, victim assistance) referrals should be made. Pharmacists should be encouraged
        to identify and consult with other relevant health care providers to enhance care
        coordination. Evidence suggests that reasonable and relevant protocols can enhance safe
        medication use and access, although onerous protocols can limit pharmacist and patient
        uptake. An example is provided by oseltamivir (Tamiflu), a flu medication reclassified from
        prescription only to pharmacist only in 2007 in New Zealand.<sup>
          <xref ref-type="bibr" rid="bibr25-0092861512460757">25</xref>,<xref ref-type="bibr" rid="bibr26-0092861512460757">26</xref>
        </sup> The oseltamivir restrictions included sales only to patients presenting at the
        pharmacy, at least 12 years of age, and for the treatment of seasonal influenza only
        (limited to May through September). These restrictions, in place due to fears of
        misdiagnosis and Internet sales, limited uptake by patients too sick to get to the pharmacy,
        and also prevented purchase in advance of travel to highly infectious areas. In 2009 the
        in-person presentation requirement was removed. Pharmacists noted that protocol and rules
        reminder cards were very useful for implementing and adhering to program guidelines.<sup>
          <xref ref-type="bibr" rid="bibr25-0092861512460757">25</xref>,<xref ref-type="bibr" rid="bibr26-0092861512460757">26</xref>
        </sup>
      </p>
      <p>In Australia the asthma reliever salbutamol (aka albuterol, Ventolin<sup>®</sup>) has long
        been available without a prescription in pharmacies. With only a pharmacist supervision
        requirement in place, an early 2007 study found 84% of simulated patient visits resulted in
        an assessment, while 24% resulted in counseling.<sup>
          <xref ref-type="bibr" rid="bibr27-0092861512460757">27</xref>
        </sup> The simulated patient requested the drug by name. A median of 2 questions were asked.
        The most frequently asked questions (in order) focused on prior Ventolin use, patient
        identity, concomitant medications, if they had consulted a physician, and frequency of use.<sup>
          <xref ref-type="bibr" rid="bibr27-0092861512460757">27</xref>
        </sup> This study shows that even in the absence of a required protocol, pharmacists
        provided basic counseling for their patients. The questions asked were consistent with the 6
        generic Australian quality standard foci of patient identity, symptoms, duration of
        symptoms, treatments tried, treatment effectiveness, and other medical conditions.<sup>
          <xref ref-type="bibr" rid="bibr27-0092861512460757">27</xref>
        </sup>
      </p>
      <p>Medications made available through policy changes should have a meaningful impact on
        patient care. Reducing the product strength from an effective dose to appease safety
        concerns is unlikely to prove successful. In the UK, for example, one reason pharmacists
        have indicated for not recommending simvastatin is lack of solid evidence for the
        effectiveness of the approved 10 mg product compared to prescription strength formulations.<sup>
          <xref ref-type="bibr" rid="bibr26-0092861512460757">26</xref>
        </sup> In addition, medicines selected for the third category should not have equivalent or
        superior OTC alternatives. Only 33% of pharmacists prescribed a medication from the limited
        formulary of the Florida Pharmacist Self-Care Consultant Law. Both Florida officials and
        pharmacists agreed that the main reason the formulary medications were not prescribed to
        patients was the availability of equally effective OTC medications.<sup>
          <xref ref-type="bibr" rid="bibr5-0092861512460757">5</xref>
        </sup>
      </p>
    </sec>
    <sec id="section4-0092861512460757">
      <title>Application of Expanded OTC Policy</title>
      <p>Many health conditions could benefit from enhanced OTC medication availability (<xref ref-type="table" rid="table1-0092861512460757">Table 2</xref>). Chronic conditions include
        migraines, allergic rhinitis, asthma, hypertension, and erectile dysfunction, among others.
        Acute conditions include pain, skin irritations or infections, and gastrointestinal
        problems. Health promotion situations could include women’s health (prenatal vitamins with
        folic acid 1 mg to prevent spina bifida, birth control to prevent pregnancy), smoking
        cessation, and motion sickness, among others. Two medical conditions that could benefit from
        expanded OTC availability, migraines and allergic rhinitis, are discussed briefly below.</p>
      <sec id="section5-0092861512460757">
        <title>Migraine Headaches and Triptans</title>
        <p>Migraines in the US resulted in an estimated 112 million bedridden days and cost
          approximately US$13 billion in missed workdays and poor work functioning in 1999.<sup>
            <xref ref-type="bibr" rid="bibr28-0092861512460757">28</xref>
          </sup> More recently, 38% of surveyed migraine sufferers reported 4.7 lost productivity
          days (absenteeism and presenteeism) over a 2-week recall period.<sup>
            <xref ref-type="bibr" rid="bibr29-0092861512460757">29</xref>
          </sup> Triptans can help prevent disabling migraine attacks, but must be taken as soon as
          possible after headache onset.<sup>
            <xref ref-type="bibr" rid="bibr30-0092861512460757">30</xref>,<xref ref-type="bibr" rid="bibr31-0092861512460757">31</xref>
          </sup> Although triptans are prescription only in the US, they are pharmacist or pharmacy
          only in New Zealand,<sup>
            <xref ref-type="bibr" rid="bibr32-0092861512460757">32</xref>
          </sup> the UK, and Germany.<sup>
            <xref ref-type="bibr" rid="bibr33-0092861512460757">33</xref>
          </sup> Pharmacists can diagnose migraine headaches,<sup>
            <xref ref-type="bibr" rid="bibr34-0092861512460757">34</xref>
          </sup> screen for risk factors that would contradict triptan use,<sup>
            <xref ref-type="bibr" rid="bibr35-0092861512460757">35</xref>
          </sup> and triage<sup>
            <xref ref-type="bibr" rid="bibr36-0092861512460757">36</xref>
          </sup> using validated protocols. Under conditions for safe use, pharmacists could assist
          patients through the use of an algorithm for appropriate use as suggested by the FDA.<sup>
            <xref ref-type="bibr" rid="bibr2-0092861512460757">2</xref>
          </sup> Alternatively, a common diagnostic protocol for migraines could be used by US
          pharmacists, as is done in the UK.<sup>
            <xref ref-type="bibr" rid="bibr37-0092861512460757">37</xref>
          </sup> The migraine protocol also includes physician referral guidelines, for example, if
          a patient has migraine headaches on more than 10 days in any one month or if the patient
          reports a change in the migraine headache pattern.<sup>
            <xref ref-type="bibr" rid="bibr37-0092861512460757">37</xref>
          </sup> Community pharmacists could help patients safely and expeditiously manage their
          migraine headaches if triptans were available as an expanded OTC. This would improve
          migraine sufferers’ timely access to triptans, potentially reduce pain and suffering, and
          result in greater workforce productivity.<sup>
            <xref ref-type="bibr" rid="bibr38-0092861512460757">38</xref>
          </sup>
        </p>
      </sec>
      <sec id="section6-0092861512460757">
        <title>Allergic Rhinitis and Intranasal Steroids</title>
        <p>Allergic Rhinitis is a common chronic condition affecting 10% to 30% of all adults and
          40% of children annually.<sup>
            <xref ref-type="bibr" rid="bibr39-0092861512460757">39</xref>
          </sup> Approximately half of the adult population experiences symptoms for more than 4
          months annually.<sup>
            <xref ref-type="bibr" rid="bibr40-0092861512460757">40</xref>
          </sup> Along with physical discomfort, rhinitis symptoms also have substantial impact on
          nonphysical aspects (quality of life, somnolence), social interactions, and cognitive abilities.<sup>
            <xref ref-type="bibr" rid="bibr40-0092861512460757">40</xref>,<xref ref-type="bibr" rid="bibr41-0092861512460757">41</xref>
          </sup> The total direct and indirect costs (absenteeism and loss of productivity) sum to
          US$5.3 to US$7.7 billion annually, making it the fifth most expensive condition in the US.<sup>
            <xref ref-type="bibr" rid="bibr40-0092861512460757">40</xref>,<xref ref-type="bibr" rid="bibr42-0092861512460757">42</xref>
          </sup> As per the American Academy of Allergy, Asthma and Immunology guidelines,
          intranasal corticosteroids (INCSs) should be the recommended first-line therapy for
          allergic rhinitis in adults and children.<sup>
            <xref ref-type="bibr" rid="bibr43-0092861512460757">43</xref>
          </sup> INCSs are associated with certain side effects but have low systemic absorption and
          an excellent safety profile. In Australia, certain formulations of beclomethasone (50
          mcg/dose), budesonide (32 mcg/dose), and mometasone (50 mcg/dose) are available as
          pharmacist only medications.<sup>
            <xref ref-type="bibr" rid="bibr44-0092861512460757">44</xref>
          </sup> A pharmacist’s oversight could be useful in educating patients about INCS time of
          onset, adding other medication for immediate relief, and treatment administration and adherence.<sup>
            <xref ref-type="bibr" rid="bibr44-0092861512460757">44</xref>
          </sup>
        </p>
      </sec>
      <sec id="section7-0092861512460757">
        <title>Patient Out-of-Pocket Cost</title>
        <p>The financial impact of expanded OTC medications will depend on multiple factors,
          including (1) whether consumers have existing insurance coverage for prescription and/or
          OTC medications, (2) whether insurance plans will cover the expanded OTC medications and
          related pharmacist clinical services, and (3) if consumers shift to prescription drugs in
          preference to an expanded OTC medication. Evidence suggests this can be a win-win
          situation for consumers, pharmacies, and health plans.<sup>
            <xref ref-type="bibr" rid="bibr45-0092861512460757">45</xref>
          </sup> When the Arkansas State Employee Benefits Division began covering OTC omeprazole in
          2004, beneficiary copayments were decreased by US$0.50 per claim and pharmacy dispensing
          fees increased by US$1.89 per claim, yet at the same time the state realized a 38% net
          savings. Reported savings resulted primarily from drug acquisition costs: the analysis did
          not include potential cost savings resulting from improved medication use or reduced
          emergency department or primary care physician office visits.<sup>
            <xref ref-type="bibr" rid="bibr45-0092861512460757">45</xref>
          </sup> Pharmacists were reimbursed at approximately 80% of physician rates.<sup>
            <xref ref-type="bibr" rid="bibr45-0092861512460757">45</xref>
          </sup> Moreover, competition by pharmaceutical companies for expanded OTC market share and
          between pharmacies could also result in increased access and decreased patient costs.<sup>
            <xref ref-type="bibr" rid="bibr46-0092861512460757">46</xref>
          </sup>
        </p>
        <p>Evidence suggests the majority of patients are willing to pay pharmacists directly for
          clinical pharmacy services.<sup>
            <xref ref-type="bibr" rid="bibr47-0092861512460757">47</xref>,<xref ref-type="bibr" rid="bibr48-0092861512460757">48</xref>
          </sup> One study found up to 70% of patients willing to pay a 20% coinsurance for pharmacy services.<sup>
            <xref ref-type="bibr" rid="bibr48-0092861512460757">48</xref>
          </sup> Allowing patients to use their health care flexible spending accounts would likely
          increase their willingness to purchase these services, potentially increasing patient
          involvement in choosing appropriate and cost-effective medications and services.</p>
      </sec>
    </sec>
    <sec id="section8-0092861512460757">
      <title>Conclusion</title>
      <p>The FDA is proposing the expanded OTC medication policy to improve patient access to
        medications. Patients would be able to purchase these medications under the supervision of a
        qualified health care professional. Pharmacists are logically the ones to fulfill this
        obligation given their training and availability in community pharmacy practice. Other
        industrialized nations have similar policies. The Scottish MAS program resulted in more
        efficient use of primary care physicians by directing patients with minor health conditions
        that could be managed with medication to community pharmacists. Pharmacists can guide and
        monitor the appropriate use of medications for health conditions that can have a significant
        impact on a patient’s quality of life and work productivity. Clinically relevant and useful
        medications and dosages should be selected. Medication use guidelines should not be so
        restrictive as to defeat the intent of the policy to expand access to medications. The
        proposed FDA policy is a long-overdue change that will help optimize available health
        personnel resources for patient care.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict" id="fn1-0092861512460757">
        <label>Declaration of Conflicting Interests</label>
        <p>The author(s) declared no potential conflicts of interest with respect to the research,
          authorship, and/or publication of this article.</p>
      </fn>
      <fn fn-type="financial-disclosure" id="fn2-0092861512460757">
        <label>Funding</label>
        <p>The author(s) received no financial support for the research, authorship, and/or
          publication of this article. </p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-0092861512460757">
        <label>1</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Brass</surname>
              <given-names>EP</given-names>
            </name>
          </person-group>. <article-title>Changing the status of drugs from prescription to
            over-the-counter availability</article-title>. <source>N Engl J Med</source>.
            <year>2001</year>;<volume>345</volume>(<issue>11</issue>):<fpage>810</fpage>–<lpage>816</lpage>.</citation>
      </ref>
      <ref id="bibr2-0092861512460757">
        <label>2</label>
        <citation citation-type="book" xlink:type="simple">
          <collab collab-type="author" xlink:type="simple">Food and Drug Administration HHS</collab>. <comment>Using
            innovative technologies and other conditions of safe use to expand which drug products
            can be considered nonprescription; public hearing: docket no. FDA-2012-N-0171;
            2012:12059-12062</comment>.</citation>
      </ref>
      <ref id="bibr3-0092861512460757">
        <label>3</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hofer</surname>
              <given-names>AN</given-names>
            </name>
            <name name-style="western">
              <surname>Abraham</surname>
              <given-names>JM</given-names>
            </name>
            <name name-style="western">
              <surname>Moscovice</surname>
              <given-names>I</given-names>
            </name>
          </person-group>. <article-title>Expansion of coverage under the patient protection and
            affordable care act and primary care utilization</article-title>. <source>Milbank
            Q</source>.
            <year>2011</year>;<volume>89</volume>(<issue>1</issue>):<fpage>68</fpage>–<lpage>89</lpage>.</citation>
      </ref>
      <ref id="bibr4-0092861512460757">
        <label>4</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Sargen</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Hooker</surname>
              <given-names>RS</given-names>
            </name>
            <name name-style="western">
              <surname>Cooper</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>. <article-title>Gaps in the supply of physicians, advance practice nurses,
            and physician assistants</article-title>. <source>J Am Coll Surg</source>.
            <year>2011</year>;<volume>212</volume>(<issue>6</issue>):<fpage>991</fpage>–<lpage>999</lpage>.</citation>
      </ref>
      <ref id="bibr5-0092861512460757">
        <label>5</label>
        <citation citation-type="web" xlink:type="simple">
          <collab collab-type="author" xlink:type="simple">US General Accounting Office</collab>. <year>1995</year>.
            <article-title>Report to the ranking minority member, Committee on Commerce, House of
            Representatives. Nonprescription drugs. Value of a pharmacist-controlled class has yet
            to be demonstrated</article-title>. <comment>GAO/PEMD-95-12. Available at</comment>:
            <ext-link ext-link-type="uri" xlink:href="http://www.gao.gov/archive/1995/pe95012.pdf" xlink:type="simple">http://www.gao.gov/archive/1995/pe95012.pdf</ext-link>. <comment>Accessed November 29,
            2011</comment>.</citation>
      </ref>
      <ref id="bibr6-0092861512460757">
        <label>6</label>
        <citation citation-type="web" xlink:type="simple">
          <collab collab-type="author" xlink:type="simple">US General Accounting Office</collab>. <year>2009</year>.
            <article-title>Nonprescription drugs. Considerations regarding a behind-the-counter drug
            class</article-title>. <comment>GAO-09-245. Available at</comment>: <ext-link ext-link-type="uri" xlink:href="http://www.gao.gov/new.items/d09245.pdf" xlink:type="simple">http://www.gao.gov/new.items/d09245.pdf</ext-link>. <comment>Accessed November 29,
            2011</comment>.</citation>
      </ref>
      <ref id="bibr7-0092861512460757">
        <label>7</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ried</surname>
              <given-names>LD</given-names>
            </name>
            <name name-style="western">
              <surname>Huston</surname>
              <given-names>SA</given-names>
            </name>
            <name name-style="western">
              <surname>Kucukarslan</surname>
              <given-names>SN</given-names>
            </name>
            <name name-style="western">
              <surname>Sogol</surname>
              <given-names>EM</given-names>
            </name>
            <name name-style="western">
              <surname>Schafermeyer</surname>
              <given-names>KW</given-names>
            </name>
            <name name-style="western">
              <surname>Sansgiry</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>. <article-title>Risks, benefits, and issues in creating a
            behind-the-counter category of medications</article-title>. <source>J Am Pharm
            Assoc</source>.
            <year>2011</year>;<volume>51</volume>(<issue>1</issue>):<fpage>26</fpage>–<lpage>39</lpage>.</citation>
      </ref>
      <ref id="bibr8-0092861512460757">
        <label>8</label>
        <citation citation-type="web" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Maddux</surname>
              <given-names>MS</given-names>
            </name>
            <name name-style="western">
              <surname>Webb</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>. <article-title>Docket reference: 2007N-0356-Behind the counter
            availability of certain drugs</article-title>. <issue>November 14</issue>,
            <year>2007</year>. <comment>Available at</comment>: <ext-link ext-link-type="uri" xlink:href="http://www.accp.com/docs/positions/commentaries/FDA-BTC%20ACCP%20Comments%20Final.pdf" xlink:type="simple">http://www.accp.com/docs/positions/commentaries/FDA-BTC%20ACCP%20Comments%20Final.pdf</ext-link>.
            <comment>Accessed November 29, 2011</comment>.</citation>
      </ref>
      <ref id="bibr9-0092861512460757">
        <label>9</label>
        <citation citation-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Giberson</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Yoder</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Lee</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>. <source>Improving Patient and Health System Outcomes Through Advanced
            Pharmacy Practice: A Report to the U.S. Surgeon General</source>. <comment>Office of the
            Chief Pharmacist</comment>. <publisher-loc>Washington, DC</publisher-loc>:
            <publisher-name>US Public Health Service</publisher-name>; <year>2011</year>.</citation>
      </ref>
      <ref id="bibr10-0092861512460757">
        <label>10</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ried</surname>
              <given-names>LD</given-names>
            </name>
            <name name-style="western">
              <surname>Huston</surname>
              <given-names>SA</given-names>
            </name>
            <name name-style="western">
              <surname>Kucukarslan</surname>
              <given-names>SN</given-names>
            </name>
            <name name-style="western">
              <surname>Sogol</surname>
              <given-names>E</given-names>
            </name>
            <name name-style="western">
              <surname>Schafermeyer</surname>
              <given-names>KW</given-names>
            </name>
            <name name-style="western">
              <surname>Sansgiry</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>. <article-title>Risks, benefits, and issues in creating a
            behind-the-counter category of medications</article-title>. <source>J Am Pharm
            Assoc</source>.
            <year>2011</year>;<volume>51</volume>(<issue>1</issue>):<fpage>26</fpage>–<lpage>39</lpage>.</citation>
      </ref>
      <ref id="bibr11-0092861512460757">
        <label>11</label>
        <citation citation-type="web" xlink:type="simple">
          <collab collab-type="author" xlink:type="simple">American Pharmacists Association</collab>.
            <article-title>Federal government begins implementation of nationwide, interoperable
            health record system: where does pharmacy plug in?Summary and analysis of CMS and ONC
            proposed rules on electronic health records and meaningful use</article-title>.
            <comment>Available at</comment>: <ext-link ext-link-type="uri" xlink:href="http://www.pharmacist.com/AM/Template.cfm?Section=Government_Affairs&amp;CONTENTID=22724&amp;TEMPLATE=/CM/ContentDisplay.cfm" xlink:type="simple">http://www.pharmacist.com/AM/Template.cfm?Section=Government_Affairs&amp;CONTENTID=22724&amp;TEMPLATE=/CM/ContentDisplay.cfm</ext-link>.<comment>November
            29, 2011</comment>.</citation>
      </ref>
      <ref id="bibr12-0092861512460757">
        <label>12</label>
        <citation citation-type="book" xlink:type="simple">
          <collab collab-type="author" xlink:type="simple">American Medical Association</collab>.
            <article-title>Preliminary report of Reference Committee B. House of
            Delegates</article-title>. <comment>2012 Meeting of the AMA 2012</comment>.</citation>
      </ref>
      <ref id="bibr13-0092861512460757">
        <label>13</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hogue</surname>
              <given-names>MD</given-names>
            </name>
            <name name-style="western">
              <surname>Grabenstein</surname>
              <given-names>JD</given-names>
            </name>
            <name name-style="western">
              <surname>Foster</surname>
              <given-names>SL</given-names>
            </name>
            <name name-style="western">
              <surname>Rothholz</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>. <article-title>Pharmacist involvement with immunizations: a decade of
            professional advancement</article-title>. <source>J Am Pharm Assoc</source>.
            <year>2006</year>;<volume>46</volume>(<issue>2</issue>):<fpage>168</fpage>–<lpage>182</lpage>.</citation>
      </ref>
      <ref id="bibr14-0092861512460757">
        <label>14</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hunt</surname>
              <given-names>TL</given-names>
            </name>
            <name name-style="western">
              <surname>Culbertson</surname>
              <given-names>VL</given-names>
            </name>
            <name name-style="western">
              <surname>Erramouspe</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Casperson</surname>
              <given-names>K</given-names>
            </name>
          </person-group>. <article-title>Perceptions of practicing pharmacists in Idaho about a
            potential behind-the-counter drug program</article-title>. <source>Ann
            Pharmacother</source>.
            <year>2010</year>;<volume>44</volume>:<fpage>1403</fpage>–<lpage>1409</lpage>.</citation>
      </ref>
      <ref id="bibr15-0092861512460757">
        <label>15</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Sega</surname>
              <given-names>T</given-names>
            </name>
            <name name-style="western">
              <surname>Sullivan</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>. <article-title>Assessment of pharmacists’ opinions toward the
            behind-the-counter category of medications</article-title>. <source>J Am Pharm
            Assoc</source>.
            <year>2011</year>;<volume>51</volume>(<issue>4</issue>):<fpage>535</fpage>–<lpage>538</lpage>.</citation>
      </ref>
      <ref id="bibr16-0092861512460757">
        <label>16</label>
        <citation citation-type="book" xlink:type="simple">
          <collab collab-type="author" xlink:type="simple">World Self-Medication Industry</collab>.
            <source>Switch—Prescription to Nonprescription Medicines Switch</source>.
            <publisher-loc>Ferney-Voltaire, France</publisher-loc>: <publisher-name>World
            Self-Medication Industry</publisher-name>; <year>2009</year>.</citation>
      </ref>
      <ref id="bibr17-0092861512460757">
        <label>17</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Sibbald</surname>
              <given-names>B</given-names>
            </name>
          </person-group>. <article-title>Ibuprofen should go behind-the-counter says expert
            panel</article-title>. <source>Can Med Assoc J</source>.
            <year>2006</year>;<volume>175</volume>(<issue>3</issue>):<fpage>233</fpage>–<lpage>234</lpage>.</citation>
      </ref>
      <ref id="bibr18-0092861512460757">
        <label>18</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Emmerton</surname>
              <given-names>L</given-names>
            </name>
            <name name-style="western">
              <surname>Shaw</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Kheir</surname>
              <given-names>N</given-names>
            </name>
          </person-group>. <article-title>Asthma management by New Zealand pharmacists: a
            pharmaceutical care demonstration project</article-title>. <source>J Clin Pharm
            Ther</source>.
            <year>2003</year>;<volume>28</volume>(<issue>5</issue>):<fpage>395</fpage>–<lpage>402</lpage>.</citation>
      </ref>
      <ref id="bibr19-0092861512460757">
        <label>19</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Gilbert</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Rao</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Quintrell</surname>
              <given-names>N</given-names>
            </name>
          </person-group>. <article-title>A review of pharmaceutical scheduling processes in six
            countries and the effect on consumer access to medicines</article-title>. <source>Int J
            Pharm Pract</source>.
            <year>2006</year>;<volume>14</volume>:<fpage>1</fpage>–<lpage>10</lpage>.</citation>
      </ref>
      <ref id="bibr20-0092861512460757">
        <label>20</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Banken</surname>
              <given-names>JA</given-names>
            </name>
            <name name-style="western">
              <surname>Foster</surname>
              <given-names>H</given-names>
            </name>
          </person-group>. <article-title>Dextromethorphan: an emerging drug of
            abuse</article-title>. <source>Ann N Y Acad Sci</source>.
            <year>2008</year>;<volume>1139</volume>:<fpage>402</fpage>–<lpage>411</lpage>.</citation>
      </ref>
      <ref id="bibr21-0092861512460757">
        <label>21</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Cooper</surname>
              <given-names>RJ.</given-names>
            </name>
          </person-group>
          <article-title>Over-the-counter medicine abuse—a review of the literature [published
            online ahead of print October 3, 2011]</article-title>. <source>J Subst Use</source>.
            <comment>doi:10.3109/14659891.2011.615002</comment>.</citation>
      </ref>
      <ref id="bibr22-0092861512460757">
        <label>22</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Wagner</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Noyce</surname>
              <given-names>PR</given-names>
            </name>
            <name name-style="western">
              <surname>Ashcroft</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>. <article-title>Changing patient consultation patterns in primary care: an
            investigation of uptake of the Minor Ailments Service in Scotland</article-title>.
            <source>Health Policy</source>.
            <year>2011</year>;<volume>99</volume>(<issue>1</issue>):<fpage>44</fpage>–<lpage>51</lpage>.</citation>
      </ref>
      <ref id="bibr23-0092861512460757">
        <label>23</label>
        <citation citation-type="web" xlink:type="simple">
          <collab collab-type="author" xlink:type="simple">NHS National Services Scotland</collab>.
            <article-title>Community Pharmacy Local Minor Ailment Service (MAS)
            Formularies</article-title>. <issue>May 23</issue>, <year>2012</year>.
            <comment>Available at</comment>: <ext-link ext-link-type="uri" xlink:href="http://www.communitypharmacy.scot.nhs.uk/local_formularies.html" xlink:type="simple">http://www.communitypharmacy.scot.nhs.uk/local_formularies.html</ext-link>.
            <comment>Accessed July 10, 2012</comment>.</citation>
      </ref>
      <ref id="bibr24-0092861512460757">
        <label>24</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Bojke</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Gravelle</surname>
              <given-names>H</given-names>
            </name>
            <name name-style="western">
              <surname>Hassell</surname>
              <given-names>K</given-names>
            </name>
            <name name-style="western">
              <surname>Whittington</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>. <article-title>Increasing patient choice in primary care: the management
            of minor ailments</article-title>. <source>Health Econ</source>.
            <year>2004</year>;<volume>13</volume>:<fpage>73</fpage>–<lpage>86</lpage>.</citation>
      </ref>
      <ref id="bibr25-0092861512460757">
        <label>25</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Gauld</surname>
              <given-names>N</given-names>
            </name>
            <name name-style="western">
              <surname>Kelly</surname>
              <given-names>F</given-names>
            </name>
            <name name-style="western">
              <surname>Shaw</surname>
              <given-names>J</given-names>
            </name>
          </person-group>. <article-title>Is non-prescription oseltamivir availability under strict
            criteria workable? A qualitative study in New Zealand</article-title>. <source>J
            Antimicrob Chemother</source>.
            <year>2011</year>;<volume>66</volume>(<issue>1</issue>):<fpage>201</fpage>–<lpage>204</lpage>.</citation>
      </ref>
      <ref id="bibr26-0092861512460757">
        <label>26</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Stewart</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>John</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Cunningham</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>McCaig</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Hansford</surname>
              <given-names>D</given-names>
            </name>
          </person-group>. <article-title>A comparison of community pharmacists’ views of
            over-the-counter omeprazole and simvastatin</article-title>. <source>Pharmacoepidemiol
            Drug Saf</source>.
            <year>2007</year>;<volume>16</volume>(<issue>12</issue>):<fpage>1290</fpage>–<lpage>1297</lpage>.</citation>
      </ref>
      <ref id="bibr27-0092861512460757">
        <label>27</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Schneider</surname>
              <given-names>CR</given-names>
            </name>
            <name name-style="western">
              <surname>Everett</surname>
              <given-names>AW</given-names>
            </name>
            <name name-style="western">
              <surname>Geelhoed</surname>
              <given-names>E</given-names>
            </name>
            <name name-style="western">
              <surname>Kendall</surname>
              <given-names>PA</given-names>
            </name>
            <name name-style="western">
              <surname>Clifford</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>. <article-title>Measuring the assessment and counseling provided with the
            supply of nonprescription asthma reliever medication: a simulated patient
            study</article-title>. <source>Ann Pharmacother</source>.
            <year>2009</year>;<volume>43</volume>(<issue>9</issue>):<fpage>1512</fpage>–<lpage>1518</lpage>.</citation>
      </ref>
      <ref id="bibr28-0092861512460757">
        <label>28</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hu</surname>
              <given-names>XH</given-names>
            </name>
            <name name-style="western">
              <surname>Markson</surname>
              <given-names>LE</given-names>
            </name>
            <name name-style="western">
              <surname>Lipton</surname>
              <given-names>RB</given-names>
            </name>
            <name name-style="western">
              <surname>Stewart</surname>
              <given-names>WF</given-names>
            </name>
            <name name-style="western">
              <surname>Berger</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>. <article-title>Burden of migraine in the United States—disability and
            economic costs</article-title>. <source>Arch Intern Med</source>.
            <year>1999</year>;<volume>159</volume>(<issue>8</issue>):<fpage>813</fpage>–<lpage>818</lpage>.</citation>
      </ref>
      <ref id="bibr29-0092861512460757">
        <label>29</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Stewart</surname>
              <given-names>WF</given-names>
            </name>
            <name name-style="western">
              <surname>Wood</surname>
              <given-names>GC</given-names>
            </name>
            <name name-style="western">
              <surname>Reed</surname>
              <given-names>ML</given-names>
            </name>
            <name name-style="western">
              <surname>Lipton</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>. <article-title>Work impact of migraine headaches</article-title>.
            <source>J Occup Environ Med</source>.
            <year>2008</year>;<volume>50</volume>:<fpage>736</fpage>–<lpage>745</lpage>.</citation>
      </ref>
      <ref id="bibr30-0092861512460757">
        <label>30</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Aurora</surname>
              <given-names>SK</given-names>
            </name>
            <name name-style="western">
              <surname>Barrodale</surname>
              <given-names>PM</given-names>
            </name>
            <name name-style="western">
              <surname>McDonald</surname>
              <given-names>SA</given-names>
            </name>
            <name name-style="western">
              <surname>Jakubowski</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Burstein</surname>
              <given-names>R</given-names>
            </name>
          </person-group>. <article-title>Revisiting the efficacy of sumatriptan therapy during the
            aura phase of migraine</article-title>. <source>Headache</source>.
            <year>2009</year>;<volume>49</volume>(<issue>7</issue>):<fpage>1001</fpage>–<lpage>1004</lpage>.</citation>
      </ref>
      <ref id="bibr31-0092861512460757">
        <label>31</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Pascual</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Vila</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>McGown</surname>
              <given-names>CC</given-names>
            </name>
          </person-group>. <article-title>Almotriptan: a review of 10 years’ clinical
            experience</article-title>. <source>Expert Rev Neurother</source>.
            <year>2010</year>;<volume>10</volume>(<issue>10</issue>):<fpage>1505</fpage>–<lpage>1517</lpage>.</citation>
      </ref>
      <ref id="bibr32-0092861512460757">
        <label>32</label>
        <citation citation-type="web" xlink:type="simple">
          <collab collab-type="author" xlink:type="simple">New Zealand Medicines and Medical Devices Safety
            Authority</collab>. <article-title>Med safe. Information for health professionals.
            Classification of medicines</article-title>. <comment>Available at</comment>: <ext-link ext-link-type="uri" xlink:href="http://www.medsafe.govt.nz/profs/class/classification.asp" xlink:type="simple">http://www.medsafe.govt.nz/profs/class/classification.asp</ext-link>. <comment>Accessed
            November 29, 2011</comment>.</citation>
      </ref>
      <ref id="bibr33-0092861512460757">
        <label>33</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Tfelt-Hansen</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Steiner</surname>
              <given-names>TJ</given-names>
            </name>
          </person-group>. <article-title>Over-the-counter triptans for migraine: what are the
            implications?</article-title>
          <source>CNS Drugs</source>.
            <year>2007</year>;<volume>21</volume>(<issue>11</issue>):<fpage>877</fpage>–<lpage>883</lpage>.</citation>
      </ref>
      <ref id="bibr34-0092861512460757">
        <label>34</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Diener</surname>
              <given-names>HC</given-names>
            </name>
            <name name-style="western">
              <surname>Dowson</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Whicker</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Bacon</surname>
              <given-names>T</given-names>
            </name>
          </person-group>. <article-title>Development and validation of a pharmacy migraine
            questionnaire to assess suitability for treatment with a triptan</article-title>.
            <source>J Headache Pain</source>.
            <year>2008</year>;<volume>9</volume>(<issue>6</issue>):<fpage>359</fpage>–<lpage>365</lpage>.</citation>
      </ref>
      <ref id="bibr35-0092861512460757">
        <label>35</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Martin</surname>
              <given-names>VT</given-names>
            </name>
            <name name-style="western">
              <surname>Goldstein</surname>
              <given-names>JA.</given-names>
            </name>
          </person-group>
          <article-title>Evaluating the safety and tolerability profile of acute treatments for
            migraine</article-title>. <source>Am J Med</source>.
            <year>2005</year>;<volume>118</volume>(<issue>suppl
            1</issue>):<fpage>36S</fpage>–<lpage>44</lpage>S.</citation>
      </ref>
      <ref id="bibr36-0092861512460757">
        <label>36</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Lipton</surname>
              <given-names>RB</given-names>
            </name>
            <name name-style="western">
              <surname>Stewart</surname>
              <given-names>WF</given-names>
            </name>
            <name name-style="western">
              <surname>Sawyer</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Edmeads</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>. <article-title>Clinical utility of an instrument assessing migraine
            disability: the Migraine Disability Assessment (MIDAS) questionnaire</article-title>.
            <source>Headache</source>.
            <year>2001</year>;<volume>41</volume>(<issue>9</issue>):<fpage>854</fpage>–<lpage>861</lpage>.</citation>
      </ref>
      <ref id="bibr37-0092861512460757">
        <label>37</label>
        <citation citation-type="web" xlink:type="simple">
          <collab collab-type="author" xlink:type="simple">Medicines and Healthcare Products Regulatory Agency</collab>.
            <article-title>Medicines. Licensing of medicines. Legal status and reclassification.
            Lists of substances. List C</article-title>. <comment>Available at</comment>: <ext-link ext-link-type="uri" xlink:href="http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Legalstatusandreclassification/Listsofsubstances/index.htm" xlink:type="simple">http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Legalstatusandreclassification/Listsofsubstances/index.htm</ext-link>.
            <comment>Accessed July 10, 2012</comment>.</citation>
      </ref>
      <ref id="bibr38-0092861512460757">
        <label>38</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Schulman</surname>
              <given-names>EA</given-names>
            </name>
            <name name-style="western">
              <surname>Cady</surname>
              <given-names>RK</given-names>
            </name>
            <name name-style="western">
              <surname>Henry</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>. <article-title>Effectiveness of sumatriptan in reducing productivity loss
            due to migraine: results of a randomized, double-blind, placebo-controlled clinical
            trial</article-title>. <source>Mayo Clin Proc</source>.
            <year>2000</year>;<volume>75</volume>:<fpage>782</fpage>–<lpage>789</lpage>.</citation>
      </ref>
      <ref id="bibr39-0092861512460757">
        <label>39</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Wallace</surname>
              <given-names>DV</given-names>
            </name>
            <name name-style="western">
              <surname>Dykewicz</surname>
              <given-names>MS</given-names>
            </name>
            <name name-style="western">
              <surname>Bernstein</surname>
              <given-names>DI</given-names>
            </name>
            <etal/>
          </person-group>. <article-title>The diagnosis and management of rhinitis: an updated
            practice parameter</article-title>. <source>J Allergy Clin Immunol</source>.
            <year>2008</year>;<volume>122</volume>
          <issue>(2, suppl)</issue>: <fpage>S1</fpage>–<lpage>S84</lpage>.</citation>
      </ref>
      <ref id="bibr40-0092861512460757">
        <label>40</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Nathan</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>. <article-title>The burden of allergic rhinitis</article-title>.
            <source>Allergy Asthma Proc</source>.
            <year>2007</year>;<volume>28</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>9</lpage>.</citation>
      </ref>
      <ref id="bibr41-0092861512460757">
        <label>41</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Blaiss</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>. <article-title>Cognitive, social and economic costs of allergic
            rhinitis</article-title>. <source>Allergy Asthma Proc</source>.
            <year>2000</year>;<volume>21</volume>(<issue>1</issue>):<fpage>7</fpage>–<lpage>13</lpage>.</citation>
      </ref>
      <ref id="bibr42-0092861512460757">
        <label>42</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Reissman</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Price</surname>
              <given-names>T</given-names>
            </name>
            <name name-style="western">
              <surname>Leibman</surname>
              <given-names>CW</given-names>
            </name>
          </person-group>. <article-title>Cost efficiency of intranasal corticosteroid prescribing
            patterns in the management of allergic rhinitis</article-title>. <source>J Manag Care
            Pharm</source>. <year>2004</year>;<volume>10</volume>
          <issue>(1, suppl)</issue>: <fpage>S9</fpage>–<lpage>S13</lpage>.</citation>
      </ref>
      <ref id="bibr43-0092861512460757">
        <label>43</label>
        <citation citation-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>McCrory</surname>
              <given-names>DC</given-names>
            </name>
            <name name-style="western">
              <surname>Williams</surname>
              <given-names>JW</given-names>
            </name>
            <name name-style="western">
              <surname>Dolor</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>. <source>67 Management of Allergic Rhinitis in the Working-Age Population:
            Summary</source>. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>Agency
            for Healthcare Research and Quality</publisher-name>; <year>2003</year>.</citation>
      </ref>
      <ref id="bibr44-0092861512460757">
        <label>44</label>
        <citation citation-type="book" xlink:type="simple">
          <collab collab-type="author" xlink:type="simple">National Prescribing Service</collab>.
            <article-title>Management of allergic rhinitis</article-title>. <source>Pharmacy
            Letter</source>. <comment>ACN 082 034 393</comment>. <publisher-loc>Surry Hills,
            Australia</publisher-loc>: <publisher-name>National Prescribing Services
            Limited</publisher-name>; <year>2001</year>.</citation>
      </ref>
      <ref id="bibr45-0092861512460757">
        <label>45</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>West</surname>
              <given-names>DS</given-names>
            </name>
            <name name-style="western">
              <surname>Johnson</surname>
              <given-names>JT</given-names>
            </name>
            <name name-style="western">
              <surname>Hong</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>. <article-title>A 30-month evaluation of the effects on the cost and
            utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit
            coverage in a state employee health plan</article-title>. <source>J Manag Care
            Pharm</source>.
            <year>2006</year>;<volume>12</volume>(<issue>1</issue>):<fpage>25</fpage>–<lpage>32</lpage>.</citation>
      </ref>
      <ref id="bibr46-0092861512460757">
        <label>46</label>
        <citation citation-type="book" xlink:type="simple">
          <collab collab-type="author" xlink:type="simple">US General Accounting Office</collab>.
            <article-title>Nonprescription drugs: value of a pharmacist-controlled class has yet to
            be demonstrated: report to the ranking Minority Member, Committee on Commerce, House of
            Representatives</article-title>; <year>1995</year>.</citation>
      </ref>
      <ref id="bibr47-0092861512460757">
        <label>47</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Barner</surname>
              <given-names>JC</given-names>
            </name>
            <name name-style="western">
              <surname>Branvold</surname>
              <given-names>A</given-names>
            </name>
          </person-group>. <article-title>Patients’ willingness to pay for pharmacist-provided
            menopause and hormone replacement therapy consultations</article-title>. <source>Res
            Social Adm Pharm</source>.
            <year>2005</year>;<volume>1</volume>(<issue>1</issue>):<fpage>77</fpage>–<lpage>100</lpage>.</citation>
      </ref>
      <ref id="bibr48-0092861512460757">
        <label>48</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Schuh</surname>
              <given-names>MJ</given-names>
            </name>
            <name name-style="western">
              <surname>Droege</surname>
              <given-names>M</given-names>
            </name>
          </person-group>. <article-title>Cognitive services provided by pharmacists: is the public
            willing to pay for them?</article-title>
          <source>Consult Pharm</source>.
            <year>2008</year>;<volume>23</volume>(<issue>3</issue>):<fpage>223</fpage>–<lpage>230</lpage>.</citation>
      </ref>
    </ref-list>
  </back>
</article>